Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Celyad SA (1C0)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Celyad historical data, for real-time data please try another search
8.020 -0.060    -0.74%
02/10 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 18.040 / 18.340
  • Day's Range: 7.890 - 8.020
Type:  Equity
Market:  Germany
ISIN:  BE0974260896 
S/N:  A1W7Q9
Celyad 8.020 -0.060 -0.74%

Celyad Company Profile

 
Read the Celyad SA company profile to learn more about the business and the management team. View Celyad SA facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

18

Equity Type

ORD

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; Multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery / PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Contact Information

Address Axis Business Park Rue André Dumont 9
Mont-Saint-Guibert, 1435
Belgium
Phone 32 1 039 41 00
Fax 32 1 039 41 41

Top Executives

Name Age Since Title
Michel E. J. Lussier 68 2007 Co-Founder, Interim CEO & Executive Director
Marco L. Davila - 2016 Member of Scientific Advisory Board
Serge Goblet 66 2008 Non-Executive Director
Hinrich Abken - 2016 Member of Scientific Advisory Board
Marina Udier Blagovic - 2020 Independent Director
Hilde Windels 59 2017 Independent Chairwoman of the Board
Dominic G. Piscitelli 49 2020 Independent Director
Christopher LiPuma - 2022 Non-Executive Director
Margo R. Roberts 69 2018 Member of Scientific Advisory Board
Gerry Graham - - Member of Scientific Advisory Board
Ann Ager - - Member of Scientific Advisory Board
Ami Patel Shah - 2021 Non-Executive Director
Jean-Christophe Marine - - Member of Scientific Advisory Board
Andrea Gothing - 2024 Non-Executive Director
John Campbell - - Member of Scientific Advisory Board
Jonathan James - 2024 Non-Executive Director
Sage Mandel - 2024 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CYAD Price Commentary

Write your thoughts about Celyad
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email